Professional Documents
Culture Documents
Essentials
Donated blood is not transfused to the recipient until it has been processed into red cell, platelet
and fresh frozen plasma components.
Red cells are transfused in anaemia to provide adequate oxygen delivery.
Fresh frozen plasma is transfused to replace coagulation factors if haemorrhage is caused by
the simultaneous deficiency of several coagulation factors.
Platelets, i.e. thrombocytes, are indicated for the management of haemorrhage or in
thrombocytopenia to promote haemostasis where either the number or functioning of platelets
is insufficient.
In primary care, the use of blood products is usually limited to the treatment of symptomatic
chronic anaemia when no alternative treatment is available. Platelet transfusions may also
occasionally be administered, for example to patients with haematological diseases.
Blood transfusions are administered at an increasing frequency at the patients home by a
qualified nurse. In such cases, the code of practice stipulated for blood transfusions must be
closely adhered to. Home blood transfusion is only recommended for patients who have received
previous problem-free transfusions in a hospital setting.
1/9
8/23/2014
2/9
8/23/2014
Platelet transfusion
Indications
Indications for a platelet transfusion include
management of haemorrhage due to thrombocytopenia
replacement of platelets in a massive haemorrhage
supportive therapy to prevent bleeding in cancer or malignant haematological diseases if the
http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00332
3/9
8/23/2014
Aims
The platelet transfusion threshold, target platelet count and the number of units needed is based
on the nature of the underlying disease, as well as the stage and goal of its treatment. The
transfusion threshold is also influenced by other factors that increase the risk of bleeding, such as
anticoagulant therapy or a planned surgical intervention.
After cytostatic chemotherapy, when the patients bone marrow fails to produce blood cells,
prophylactic platelet transfusions are indicated when the platelet count is < 10 109 /l.
Prophylactic platelet transfusions are indicated in severe infections and during anticoagulant
therapy when the platelet count is < 2030 109 /l.
Prophylactic transfusions comprise 12 units. The response to transfusion is estimated by
measuring the platelet count before the transfusion and about one hour after, or the next
morning. After one hour, the expected post-transfusion platelet count increment following a
transfusion of two units is 4050 109 /l of which about 60% should remain the following morning.
Reduced response to a transfusion may be due to various transient causes, such as fever,
sepsis, DIC, splenomegaly, certain medicines, vasculitis and graft-versus-host reaction.
Immune refractoriness due to, for example, the presence of anti-HLA (common) or HPA- (rare)
antibodies or platelet autoantibodies may result in long-lasting poor transfusion response.
Platelet transfusions are indicated for the management of clinically significant haemorrhage in a
thrombocytopenic patient when the platelet count falls below 50 109 /l. The management of
haemorrhage needs 24 units of platelets depending on the nature and site of the bleeding as well
as the pre-transfusion platelet count. During a surgical procedure a platelet count needs to be >
50 109 /l so as not to cause or maintain bleeding.
4/9
8/23/2014
Plasma transfusion
Fresh frozen plasma (FFP) is widely used. The frozen plasma product OctaplasLG is used in some
countries. It is a registered medicinal product; see the Summary of Product Characteristics more
detailed information.
OctaplasLG must be matched for the ABO group. No compatibility testing (cross matching) is
needed for OctaplasLG. Since all red cells have been removed from the product, the RhD blood
group does not need to be considered.
In emergency situations, OctaplasLG blood group AB can be administered to all patients since
it is devoid of anti-A and anti-B isoagglutinins.
Coagulation factor assays must be carried out before the product is administered.
5/9
8/23/2014
6/9
8/23/2014
Adverse reactions
Febrile reaction
The most common reaction associated with blood transfusions
The treatment of a mild febrile reaction, with or without rigors, is symptomatic and no followup investigations are required.
Fever is a feature of many other transfusion reactions, and the patient must be observed for
the emergence of any other symptoms.
Mild allergic reaction
A common transfusion reaction, the cause of which remains unknown. The patient is likely to
be allergic to a component of the blood product.
Symptoms consist of urticaria, other pruritic erythema, swelling of the lips, tongue or pharynx
and conjunctivitis
The reaction is usually caused by a single blood unit.
The reaction can be suspected to be caused by the transfusion if symptoms emerge during the
transfusion or within 4 hours after its completion and no other cause can be identified.
Antihistamines will relieve symptoms.
No follow-up investigations are required.
Severe allergic reaction or anaphylaxis
A rare transfusion reaction
Most likely caused by plasma proteins and soluble components. The reaction is usually caused
by a single blood unit.
The aetiology of an anaphylactic reaction may involve the formation of anti-IgA antibodies
against IgA in an IgA-deficient recipient. Typically develops at the start of, or during, the
transfusion but is also possible immediately after the transfusion has been completed.
Symptoms, including dyspnoea, generalised urticaria, hypotension, nausea and loss of
consciousness may quickly become life-threatening.
The treatment of the acute phase is symptomatic.
Careful planning is needed should the patient require transfusions in the future.
It may be possible to prevent reactions to subsequent transfusions by using washed blood
components (red cells and platelets), where the majority of the donor's plasma has been
removed.
Plasma products that contain IgA cannot be transfused to a recipient with anti-IgA
antibodies (contact local transfusion safety officials, if indicated).
Acute haemolysis
http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00332
7/9
8/23/2014
8/9
8/23/2014
reaction.
Country specific legislation will provide instructions regarding
the obligation of local health care units, blood banks etc. to keep records relating to
transfusion reactions and near miss incidents
the obligation to report serious transfusion reactions, and near miss incidents, associated with
blood quality and safety to appropriate bodies
recommendations to report other events, and near miss incidents, not associated with the
blood quality.
http://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00332
9/9